Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
In Japan, the number of artificial joint procedures declined as medical institutions postponed adopting the products due to the impact of a reported incident. In the United States, the number of artificial hip procedures increased with the rollout of new products, while the number of cases and net sales declined because of delivery delays for artificial knee joint products. The cost of sales ratio deteriorated as lower production volumes increased the burden of fixed manufacturing costs and the weaker yen raised the cost of imported purchases.
No applicable matters.
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥5,325 million (YoY -10.0%) |
| Operating profit | ¥-526 million |
| Ordinary income | ¥-540 million |
| Profit attributable to owners of the parent | ¥-417 million |
| Net income per share | ¥(15.85) |
| Equity ratio | End of the current fiscal period 70.1 / End of previous period 71.2 |
| Total assets | ¥35,384 million |
| Net assets | ¥24,829 million |
| Full-year earnings forecast | Net Sales ¥25,370 million (YoY +6.1%) / Operating profit ¥430 million (YoY -25.1%) / Ordinary income ¥140 million (YoY -73.8%) / Net income ¥60 million (YoY -77.2%) |
| Annual Dividend Forecast | ¥17 → ¥17（0.0%） |
| Segment revenue | Japan ¥2,768,787 thousand (YoY -13.4%), United States ¥2,556,749 thousand (YoY -6.0%) |
| Segment profit | Japan ¥-27,942 thousand, United States ¥-497,158 thousand |
| Regional sales | ¥2,768,787 thousand, ¥2,556,749 thousand |
| Depreciation and amortization | ¥428,210 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income Not disclosed / Extraordinary loss Loss on Disposal of Fixed Assets ¥8,733 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None (対象者：Not disclosed) |
| Issued Shares at Period-End | 26,475,880 Shares |
| Treasury Shares at Period-End | 122,344 Shares |
| Factors Behind Changes in Business Performance | In Japan, the number of artificial joint procedures declined as medical institutions postponed adopting the products due to the impact of a reported incident. In the United States, the number of artificial hip procedures increased with the rollout of new products, while the number of cases and net sales declined because of delivery delays for artificial knee joint products. The cost of sales ratio deteriorated as lower production volumes increased the burden of fixed manufacturing costs and the weaker yen raised the cost of imported purchases. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In Japan, some medical institutions postponed adopting the products due to the impact of a reported incident, resulting in a decline in the number of cases. In the United States, supply constraints continued because of delivery delays for artificial knee joint products. In addition, the cost of sales ratio deteriorated because lower production volumes increased the burden of fixed manufacturing costs, while the weaker yen raised the cost of imported purchases.